Zusammenfassung
Die symptomatische Therapie des Morbus Parkinson wird in Abhängigkeit von Erkrankungsdauer
und kumulativer L-Dopa-Dosis zunehmend schwieriger. Spätkomplikationen betreffen einerseits
die Motorik in Form von Fluktuationen der Beweglichkeit und Dyskinesien. Zudem kann
es zu kognitiven Störungen mit Beeinträchtigung vor allem exekutiver Funktionen und
zu psychiatrischen Komplikationen in Form von paranoid-halluzinatorischer Psychose
und Depression kommen. Mit zunehmendem Alter und Krankheitsdauer treten auch vermehrt
Störungen des autonomen Nervensystems auf.
Abstract
Depending on duration of Parkinson's disease (PD) and on cumulative dosage of L-Dopa
symptomatic therapy becomes more complicated. Long-term complications of PD include
motor symptoms such as fluctuations of motility and dyskinesias. In addition, advanced
parkinsonian patients often present with cognitive disturbances particularly impairments
of executive functions, with psychiatric symptoms like depression and psychosis and
with autonomic failure.
Literatur
- 1
Nutt J G, Carter J H, Woodward W R.
Long-duration response to levodopa.
Neurology.
1995;
45
1613-1616
- 2
Dotto P Del, Pavese N, Gambaccini G. et al .
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind
placebo-controlled study.
Mov Disord.
2001;
16
515-520
- 3
Chase T N, Oh J D, Konitsiotis S.
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic
mechanisms.
J Neurol.
2000;
247, Suppl 2
II36-II42
- 4
Richard I H.
Depression in Parkinson's Disease.
Curr Treat Options Neurol.
2000;
2
263-274
- 5
Sawamoto N, Honda M, Hanakawa T. et al .
Cognitive slowing in Parkinson's disease: a behavioral evaluation independent of motor
slowing.
J Neurosci.
2002;
22
5198-5203
- 6
Strang R R.
Imipramine in treatment of Parkinsonism: a double-blind placebo study.
Br Med J.
1965;
54
33-34
- 7
Gony M, Lapeyre-Mestre M, Monastruc J L. et al .
Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving
antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors
and other antidepressant drugs.
Clin Neuropharmacol.
2003;
26
142-145
- 8
Emre M, Aarsland D, Albanese A. et al .
Rivastigmine for dementia associated with Parkinson's disease.
N Engl J Med.
2004;
351
2509-2518
- 9
Witjas T, Kaphan E, Azulay J P. et al .
Nonmotor fluctuations in Parkinson's disease. Frequent and disabling.
Neurology.
2002;
59
408-413
- 10
Aarsland D, Andersen K, Larsen J P. et al .
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective
study.
Arch Neurol.
2003;
60
387-392
- 11
Braune S, Reinhardt M, Schnitzler R. et al .
Cardiac uptake of [123] MIBG seperates Parkinson's disease from multiple system atrophy.
Neurology.
1999;
53
1020-1025
Prof. Dr. Michael SchwarzDirektor der Neurologischen Klinik
Klinikum Dortmund
Beurhausstraße 40
44137 Dortmund
Email: stkd.m.schwarz@dokom.net
